State Street
AVDL

State Street’s Avadel Pharmaceuticals AVDL Stock Holding History

State Street’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,278,301
Closed -$49.1M – 4276
2025
Q4 		$49.1M Sell
2,278,301
-14,306
-0.6% -$278K ﹤0.01% 1755
2025
Q3 		$35M Buy
2,292,607
+221,198
+11% +$2.88M ﹤0.01% 1930
2025
Q2 		$18.3M Buy
2,071,409
+412,103
+25% +$3.62M ﹤0.01% 2233
2025
Q1 		$13M Sell
1,659,306
-26,833
-2% -$225K ﹤0.01% 2363
2024
Q4 		$17.7M Buy
1,686,139
+62,837
+4% +$763K ﹤0.01% 2287
2024
Q3 		$21.3M Buy
1,623,302
+483,787
+42% +$7.37M ﹤0.01% 2170
2024
Q2 		$16M Buy
1,139,515
+1,102,671
+2,993% +$18M ﹤0.01% 2281
2024
Q1 		$622K Sell
36,844
-5,262
-12% -$78.4K ﹤0.01% 3593
2023
Q4 		$595K Buy
42,106
+11,800
+39% +$139K ﹤0.01% 3605
2023
Q3 		$312K Buy
30,306
+7,400
+32% +$99.1K ﹤0.01% 3793
2023
Q2 		$377K Sell
22,906
-71,493
-76% -$929K ﹤0.01% 3774
2023
Q1 		$865K Buy
94,399
+10,286
+12% +$84.6K ﹤0.01% 3580
2022
Q4 		$602K Sell
84,113
-42,022
-33% -$295K ﹤0.01% 3704
2022
Q3 		$632K Sell
126,135
-45,817
-27% -$252K ﹤0.01% 3691
2022
Q2 		$420K Sell
171,952
-33,842
-16% -$139K ﹤0.01% 3895
2022
Q1 		$1.41M Buy
205,794
+16,278
+9% +$112K ﹤0.01% 3696
2021
Q4 		$1.53M Buy
189,516
+24,732
+15% +$226K ﹤0.01% 3719
2021
Q3 		$1.61M Buy
164,784
+25,320
+18% +$199K ﹤0.01% 3665
2021
Q2 		$939K Buy
139,464
+18,771
+16% +$149K ﹤0.01% 3678
2021
Q1 		$1.09M Buy
120,693
+27,377
+29% +$221K ﹤0.01% 3604
2020
Q4 		$624K Buy
93,316
+10,518
+13% +$65.8K ﹤0.01% 3624
2020
Q3 		$417K Buy
82,798
+64,256
+347% +$468K ﹤0.01% 3590
2020
Q2 		$150K Buy
+18,542
New +$163K ﹤0.01% 3634
2019
Q4 		– Sell
-89,192
Closed -$371K – 3810
2019
Q3 		$371K Hold
89,192
– – ﹤0.01% 3543
2019
Q2 		$258K Hold
89,192
– – ﹤0.01% 3590
2019
Q1 		$128K Hold
89,192
– – ﹤0.01% 3618
2018
Q4 		$230K Hold
89,192
– – ﹤0.01% 3554
2018
Q3 		$392K Sell
89,192
-43,470
-33% -$235K ﹤0.01% 3508
2018
Q2 		$813K Sell
132,662
-3,448
-3% -$24.2K ﹤0.01% 3419
2018
Q1 		$992K Buy
136,110
+15,573
+13% +$137K ﹤0.01% 3341
2017
Q4 		$988K Buy
120,537
+88,494
+276% +$830K ﹤0.01% 3354
2017
Q3 		$336K Buy
32,043
+261
+0.8% +$2.49K ﹤0.01% 3531
2017
Q2 		$351K Buy
31,782
+523
+2% +$5.25K ﹤0.01% 3467
2017
Q1 		$302K Buy
31,259
+858
+3% +$8.58K ﹤0.01% 3458
2016
Q4 		$316K Buy
30,401
+856
+3% +$9.41K ﹤0.01% 3449
2016
Q3 		$366K Sell
29,545
-1,137
-4% -$14.9K ﹤0.01% 3335
2016
Q2 		$330K Buy
30,682
+787
+3% +$8.39K ﹤0.01% 3454
2016
Q1 		$330K Sell
29,895
-1,209
-4% -$12K ﹤0.01% 3421
2015
Q4 		$380K Buy
31,104
+602
+2% +$9.39K ﹤0.01% 3386
2015
Q3 		$498K Sell
30,502
-1,042
-3% -$22.9K ﹤0.01% 3336
2015
Q2 		$668K Buy
31,544
+440
+1% +$7.89K ﹤0.01% 3320
2015
Q1 		$559K Buy
31,104
+1,305
+4% +$20.4K ﹤0.01% 3351
2014
Q4 		$510K Sell
29,799
-1,209
-4% -$17.3K ﹤0.01% 3387
2014
Q3 		$444K Buy
+31,008
New +$446K ﹤0.01% 3396

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

State Street's AVDL Position: Q1 2026 in Review

State Street sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 2,278,301 shares — an estimated $49.1M sold.

State Street first reported a position in AVDL in Q3 2014 and held it in 44 quarters. The position peaked at $49.1M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • State Street reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • State Street sold 2,278,301 Avadel Pharmaceuticals shares in Q1 2026, an estimated $49.1M.
  • State Street first reported a position in Avadel Pharmaceuticals in Q3 2014 and held it in 44 quarters.
  • State Street's Avadel Pharmaceuticals position peaked at $49.1M in Q4 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.